169 related articles for article (PubMed ID: 33731362)
21. ASXLs binding to the PHD2/3 fingers of MLL4 provides a mechanism for the recruitment of BAP1 to active enhancers.
Zhang Y; Xie G; Lee JE; Zandian M; Sudarshan D; Estavoyer B; Benz C; Viita T; Asgaritarghi G; Lachance C; Messmer C; Simonetti L; Sinha VK; Lambert JP; Chen YW; Wang SP; Ivarsson Y; Affar EB; Côté J; Ge K; Kutateladze TG
Nat Commun; 2024 Jun; 15(1):4883. PubMed ID: 38849395
[TBL] [Abstract][Full Text] [Related]
22. Cancer associated missense mutations in BAP1 catalytic domain induce amyloidogenic aggregation: A new insight in enzymatic inactivation.
Bhattacharya S; Hanpude P; Maiti TK
Sci Rep; 2015 Dec; 5():18462. PubMed ID: 26680512
[TBL] [Abstract][Full Text] [Related]
23. Ubiquitin recognition of BAP1: understanding its enzymatic function.
Hanpude P; Bhattacharya S; Kumar Singh A; Kanti Maiti T
Biosci Rep; 2017 Oct; 37(5):. PubMed ID: 28935764
[TBL] [Abstract][Full Text] [Related]
24. Proteomic analysis identifies novel binding partners of BAP1.
Baas R; J van der Wal F; Bleijerveld OB; van Attikum H; Sixma TK
PLoS One; 2021; 16(9):e0257688. PubMed ID: 34591877
[TBL] [Abstract][Full Text] [Related]
25. Reducing hyperactivated BAP1 attenuates mutant ASXL1-driven myeloid malignancies in human haematopoietic cells.
Bai J; Chen Z; Chen C; Zhang M; Zhang Y; Song J; Yuan J; Jiang X; Xing W; Yang J; Bai J; Zhou Y
Cancer Lett; 2021 Oct; 519():78-90. PubMed ID: 34186160
[TBL] [Abstract][Full Text] [Related]
26. The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.
Abdel-Wahab O; Dey A
Leukemia; 2013 Jan; 27(1):10-5. PubMed ID: 23147254
[TBL] [Abstract][Full Text] [Related]
27. Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O.
Mashtalir N; Daou S; Barbour H; Sen NN; Gagnon J; Hammond-Martel I; Dar HH; Therrien M; Affar el B
Mol Cell; 2014 May; 54(3):392-406. PubMed ID: 24703950
[TBL] [Abstract][Full Text] [Related]
28. MBD5 and MBD6 stabilize the BAP1 complex and promote BAP1-dependent cancer.
Tsuboyama N; Szczepanski AP; Zhao Z; Wang L
Genome Biol; 2022 Sep; 23(1):206. PubMed ID: 36180891
[TBL] [Abstract][Full Text] [Related]
29. The forkhead transcription factor FOXK2 acts as a chromatin targeting factor for the BAP1-containing histone deubiquitinase complex.
Ji Z; Mohammed H; Webber A; Ridsdale J; Han N; Carroll JS; Sharrocks AD
Nucleic Acids Res; 2014 Jun; 42(10):6232-42. PubMed ID: 24748658
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia.
Wang L; Birch NW; Zhao Z; Nestler CM; Kazmer A; Shilati A; Blake A; Ozark PA; Rendleman EJ; Zha D; Ryan CA; Morgan MAJ; Shilatifard A
Nat Cancer; 2021 May; 2(5):515-526. PubMed ID: 35122023
[TBL] [Abstract][Full Text] [Related]
31. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization.
Ventii KH; Devi NS; Friedrich KL; Chernova TA; Tighiouart M; Van Meir EG; Wilkinson KD
Cancer Res; 2008 Sep; 68(17):6953-62. PubMed ID: 18757409
[TBL] [Abstract][Full Text] [Related]
32. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity.
Nishikawa H; Wu W; Koike A; Kojima R; Gomi H; Fukuda M; Ohta T
Cancer Res; 2009 Jan; 69(1):111-9. PubMed ID: 19117993
[TBL] [Abstract][Full Text] [Related]
33. B-cell intrinsic regulation of antibody mediated immunity by histone H2A deubiquitinase BAP1.
Liang Y; Wang H; Seija N; Lin YH; Tung LT; Di Noia JM; Langlais D; Nijnik A
Front Immunol; 2024; 15():1353138. PubMed ID: 38529289
[TBL] [Abstract][Full Text] [Related]
34. Regulation of B Lymphocyte Development by Histone H2A Deubiquitinase BAP1.
Lin YH; Liang Y; Wang H; Tung LT; Förster M; Subramani PG; Di Noia JM; Clare S; Langlais D; Nijnik A
Front Immunol; 2021; 12():626418. PubMed ID: 33912157
[TBL] [Abstract][Full Text] [Related]
35. BAP1 promotes the repair of UV-induced DNA damage via PARP1-mediated recruitment to damage sites and control of activity and stability.
Lee SA; Lee D; Kang M; Kim S; Kwon SJ; Lee HS; Seo HR; Kaushal P; Lee NS; Kim H; Lee C; Kwon J
Cell Death Differ; 2022 Dec; 29(12):2381-2398. PubMed ID: 35637285
[TBL] [Abstract][Full Text] [Related]
36. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.
Farley MN; Schmidt LS; Mester JL; Pena-Llopis S; Pavia-Jimenez A; Christie A; Vocke CD; Ricketts CJ; Peterson J; Middelton L; Kinch L; Grishin N; Merino MJ; Metwalli AR; Xing C; Xie XJ; Dahia PLM; Eng C; Linehan WM; Brugarolas J
Mol Cancer Res; 2013 Sep; 11(9):1061-1071. PubMed ID: 23709298
[TBL] [Abstract][Full Text] [Related]
37. Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.
Kolluri KK; Alifrangis C; Kumar N; Ishii Y; Price S; Michaut M; Williams S; Barthorpe S; Lightfoot H; Busacca S; Sharkey A; Yuan Z; Sage EK; Vallath S; Le Quesne J; Tice DA; Alrifai D; von Karstedt S; Montinaro A; Guppy N; Waller DA; Nakas A; Good R; Holmes A; Walczak H; Fennell DA; Garnett M; Iorio F; Wessels L; McDermott U; Janes SM
Elife; 2018 Jan; 7():. PubMed ID: 29345617
[TBL] [Abstract][Full Text] [Related]
38. BAP1 Missense Mutations in Cancer: Friend or Foe?
Okonska A; Felley-Bosco E
Trends Cancer; 2019 Nov; 5(11):659-662. PubMed ID: 31735283
[TBL] [Abstract][Full Text] [Related]
39. [Molecular mechanisms by which the mutant ASXL1/BAP1 complex aggravates myeloid leukemia].
Asada S
Rinsho Ketsueki; 2020; 61(4):392-405. PubMed ID: 32378586
[TBL] [Abstract][Full Text] [Related]
40. Structural basis for the activation and inhibition of the UCH37 deubiquitylase.
Vander Linden RT; Hemmis CW; Schmitt B; Ndoja A; Whitby FG; Robinson H; Cohen RE; Yao T; Hill CP
Mol Cell; 2015 Mar; 57(5):901-911. PubMed ID: 25702872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
